Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer's disease

被引:44
|
作者
Venkataraman, Ashwin V. [1 ,2 ]
Mansur, Ayla [3 ]
Rizzo, Gaia [1 ,3 ]
Bishop, Courtney [3 ]
Lewis, Yvonne [3 ]
Kocagoncu, Ece [4 ]
Lingford-Hughes, Anne [1 ]
Huiban, Mickael [3 ]
Passchier, Jan [3 ]
Rowe, James B. [4 ]
Tsukada, Hideo [5 ]
Brooks, David J. [6 ,7 ]
Martarello, Laurent [8 ]
Comley, Robert A. [9 ]
Chen, Laigao [10 ]
Schwarz, Adam J. [11 ]
Hargreaves, Richard [12 ]
Gunn, Roger N. [1 ,3 ]
Rabiner, Eugenii A. [3 ,13 ]
Matthews, Paul M. [1 ,2 ]
机构
[1] Imperial Coll London, Dept Brain Sci, London W12 0NN, England
[2] Imperial Coll London, UK Dementia Res Inst, London W12 0NN, England
[3] Invicro LLC, London W12 0NN, England
[4] Univ Cambridge, Cambridge CB2 2QQ, England
[5] Hamamatsu Photon KK, Hamamatsu, Shizuoka 4348601, Japan
[6] Newcastle Univ, Newcastle NE2 4HH, England
[7] Aarhus Univ, Dept Clin Med, DK-8200 Aarhus, Denmark
[8] Biogen, Cambridge, MA 02142 USA
[9] AbbVie, N Chicago, IL USA
[10] Pfizer Inc, Cambridge, MA 02139 USA
[11] Takeda Pharmaceut Ltd, Cambridge, MA 02139 USA
[12] Bristol Myers Squibb, Princeton, NJ 08543 USA
[13] Kings Coll London, London SE5 8AF, England
基金
英国医学研究理事会;
关键词
IN-VIVO EVALUATION; POSITRON-EMISSION-TOMOGRAPHY; OXIDATIVE STRESS; AMYLOID DEPOSITION; RECEPTOR-BINDING; BRAIN; SIGMA(1); ATROPHY; SA4503; LIGAND;
D O I
10.1126/scitranslmed.abk1051
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cell stress and impaired oxidative phosphorylation are central to mechanisms of synaptic loss and neurodegeneration in the cellular pathology of Alzheimer's disease (AD). In this study, we quantified the in vivo expression of the endoplasmic reticulum stress marker, sigma 1 receptor (S1R), using [C-11]SA4503 positron emission tomography (PET), the mitochondrial complex I (MC1) with [F-18]BCPP-EF, and the presynaptic vesicular protein SV2A with [C-11]UCB-J in 12 patients with early AD and in 16 cognitively normal controls. We integrated these molecular measures with assessments of regional brain volumes and cerebral blood flow ( CBF) measured with magnetic resonance imaging arterial spin labeling. Eight patients with AD were followed longitudinally to estimate the rate of change of the physiological and structural pathology markers with disease progression. The patients showed widespread increases in S1R (<= 27%) and regional reduction in MC1 (>= -28%) and SV2A (>= -25%) radioligand binding, brain volume (>= -23%), and CBF (>= -26%). [F-18]BCPP-EF PET MC1 binding (>= -12%) and brain volumes (>= -5%) showed progressive reductions over 12 to 18 months, suggesting that they both could be used as pharmacodynamic indicators in early-stage therapeutics trials. Associations of reduced MC1 and SV2A and increased S1R radioligand binding with reduced cognitive performance in AD, although exploratory, suggested a loss of metabolic functional reserve with disease. Our study thus provides in vivo evidence for widespread, clinically relevant cellular stress and bioenergetic abnormalities in early AD.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease
    de la Monte, Suzanne M.
    Wands, Jack R.
    JOURNAL OF ALZHEIMERS DISEASE, 2006, 9 (02) : 167 - 181
  • [2] Mitochondrial Dysfunction and Stress Responses in Alzheimer's Disease
    Weidling, Ian
    Swerdlow, Russell H.
    BIOLOGY-BASEL, 2019, 8 (02):
  • [3] Oxidative stress, mitochondrial dysfunction and Alzheimer's disease
    Georgios Hadjigeorgiou
    Annals of General Psychiatry, 7 (Suppl 1)
  • [4] Mitochondrial Dysfunction and Oxidative Stress in Alzheimer's Disease
    Misrani, Afzal
    Tabassum, Sidra
    Yang, Li
    FRONTIERS IN AGING NEUROSCIENCE, 2021, 13
  • [5] Oxidative stress and mitochondrial dysfunction in Alzheimer's disease
    Wang, Xinglong
    Wang, Wenzhang
    Li, Li
    Perry, George
    Lee, Hyoung-gon
    Zhu, Xiongwei
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2014, 1842 (08): : 1240 - 1247
  • [6] Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease
    Eckert, A
    Keil, U
    Marques, CA
    Bonert, A
    Frey, C
    Schüssel, K
    Müller, WE
    BIOCHEMICAL PHARMACOLOGY, 2003, 66 (08) : 1627 - 1634
  • [7] Mitochondrial dysfunction in Alzheimer's disease
    D'Alessandro, Maria Clara Bila
    Kanaan, Salim
    Geller, Mauro
    Pratico, Domenico
    Daher, Joao Paulo Lima
    AGEING RESEARCH REVIEWS, 2025, 107
  • [8] MITOCHONDRIAL DYSFUNCTION IN ALZHEIMER'S DISEASE
    Kota, Lakshmi Narayanan
    Nayak, Rashmitha
    Paul, Pradip
    Viswanath, Biju
    Varghese, Mathew
    Jain, Sanjeev
    Purushottam, Meera
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S840 - S841
  • [9] Mitochondrial dysfunction and Alzheimer's disease
    Maruszak, Aleksandra
    Zekanowski, Cezary
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2011, 35 (02): : 320 - 330
  • [10] Mitochondrial dysfunction and Alzheimer's disease
    Ghosh, SS
    Miller, S
    Herrnstadt, C
    Fahy, E
    Shinobu, LA
    Galasko, D
    Thal, LJ
    Beal, MF
    Howell, N
    Parker, WD
    Davis, RE
    PROGRESS IN ALZHEIMER'S AND PARKINSON'S DISEASES, 1998, 49 : 59 - 66